Coya Therapeutics Announces Publication Of Phase 1 Study On CTLA4-Ig And Interleukin-2 Combination Therapy For ALS In Frontiers In Neurology
Portfolio Pulse from Benzinga Newsdesk
Coya Therapeutics has published a Phase 1 study in Frontiers in Neurology showing promising results for its combination therapy of CTLA4-Ig and Interleukin-2 in treating ALS. The study demonstrated halting of disease progression and reduction in inflammation and oxidative stress over 24 weeks.
June 11, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coya Therapeutics' Phase 1 study on CTLA4-Ig and Interleukin-2 combination therapy for ALS shows promising results, halting disease progression and reducing inflammation over 24 weeks.
The positive results from the Phase 1 study are likely to boost investor confidence in Coya Therapeutics, potentially leading to a short-term increase in stock price. The halting of disease progression and reduction in inflammation are significant outcomes that could attract further investment and interest in the company's ALS treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100